-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Macrogenics, Lowers Price Target to $3

Benzinga·05/14/2025 15:01:16
Listen to the news
Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $8 to $3.